ZyGEM Corporation Appoints New Chief Executive to Be Based in the USA

Puntúa la noticia :

Nota de los usuarios: - (0votos)

• Bolsa, mercados y cotizaciones
• Empresas y finanzas

Share

Tweet

elEconomista.es en Twitter

Follow @eleconomistaes

EcoTablet - ¡Gratis en App Store!

La plataforma más completa de información y servicios económicos para iPad.

• Suscribirse al boletín
• Imprimir
• Enviar
• Aumentar texto
• Reducir texto
• Haga doble click sobre una palabra para ver su signifcado
• Sudoku: Juega cada día a uno nuevo
• El tiempo: Consulta la previsión para tu ciudad

ZyGEM Corp Ltd, a leading developer and manufacturer of unique
products for DNA extraction, today announced the appointment of Paul
Kinnon as President and Chief Executive Officer. He joins the company
from San Diego-based Invitrogen Corp where he held the positions of
vice president of global strategic alliances and vice president and
general manager of the Applied Markets business unit. During his
tenure, he successfully increased revenues of the Applied Markets
business unit and initiated and implemented strategic partnerships
with IDEXX Corp, and more recently, the Chinese Center for Disease
Control in advance of the 2008 Olympic Games.

ZyGEM products provide creative solutions for the life science
markets, specifically; forensics, basic research and clinical
applications using properties of unique enzymes that have been
isolated from a proprietary ZyGEM culture collection. The ZyGEM
technology and product portfolio is built around more than twenty
years research and development on ZyGEM's exclusive collection of
microorganisms and fungi from extreme environments.

"Paul Kinnon is an outstanding business leader; we are delighted
to welcome him to this CEO position as well as a board directorship.
His proven record of success at Invitrogen and 18 years in the global
life science market will significantly benefit ZyGEM, particularly as
we expand international." said Neville Jordan, ZyGEM chairman of the
board.

In his new position Paul will be charged with expanding ZyGEM
further into the North American and European-based markets. He will be
headquartered in San Diego, California.

Paul Kinnon said, "I look forward to continuing the innovative
product development and accelerating our growth, while building the
company internationally. This is an extraordinary opportunity to work
closely with a strong and influential board and to progress the New
Zealand Biotechnology sector."

Paul Kinnon, an 18-year life sciences industry veteran, whose main
areas of focus have been research-intensive pharmaceutical &
biotechnology companies, academia and, more recently, applied markets,
particularly forensics, food and water. Paul received a Bachelor of
Applied Chemistry from Coventry University and a Diploma in Marketing
from the Chartered Institute of Marketing. He holds membership in the
Association of Strategic Alliance Professionals.

About ZyGEM

ZyGEM Corporation Limited is a rapidly growing biotechnology
company with an innovative range of products, proprietary technologies
with significant global market applications. ZyGEM produces DNA
extraction and detection products, molecular biology enzymes,
individual enzymes and diagnostics. It serves customers in the life
science market including: basic research, forensics, clinical,
sustainability and agriculture.

ZyGEM's technology and product portfolio is built around more than
twenty years research and development on ZyGEM's exclusive collection
of microorganisms from extreme environments. One of the first
technologies developed and commercialized from this collection (and
covered by international patents) is ideal for extraction of DNA. The
new technology has major competitive advantages over existing and
historical methods. (www.ZyGEM.com).

PUBLICIDAD

- Recibe nuestros análisis Diarios sobre Divisas, Acciones y Opciones. ¡Apúntate ya! ¡Es GRATIS!

- Opere en más de 8.000 CFDs. Infórmese y obtenga su CFD Trading Guide

- Nuevos spreads en materias primas: Oro tan sólo 0,3 puntos, Plata 0,25, Petróleo 0,35

- Opera desde 2,95 € en tiempo real con Self Bank.